| Titre | A Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer |
| Protocole ID | IND.234G |
| ClinicalTrials.gov ID | NCT03385655 |
| Type(s) de cancer | Prostate |
| Phase | Phase II |
| Stade | Résistant à la castration - métastatique |
| Type étude | Clinique |
| Médicament | Carboplatine |
| Institution |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
| Ville | Montréal |
| Investigateur(trice) principal(e) |
Dr Fred Saad |
| Coordonnateur(trice) |
Amal Nadiri 514-890-8000 poste 26074 |
| Statut |  Actif en recrutement |
| Critètes d'éligibilité | Patients must fulfill all of the criteria set out in Section 4.0 of the main protocol AND the following eligibility/ineligibility criteria and timings specific to carboplatin to be eligible for enrollment to the substudy. Renal function defined by serum creatinine < 1.25 x ULN and creatinine clearance >/= 50 mL/min. Patients who have a severe allergic reaction to platinum-containing compounds, who had live attenuated vaccination administered within 30 days prior to enrollment or within 30 days of receiving carboplatin, or need for concomitant treatment with nephrotoxic drugs are not eligible. |
| Critètes d'exclusion |
Groupe d'étude en oncologie du Québec